|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
45
|
|
pubmed:dateCreated |
2003-11-26
|
|
pubmed:abstractText |
Epidemiological studies have found that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a lower risk of colorectal cancer (CRC). Cyclooxygenase (COX)-2 expression is present in colorectal cancer and overexpression is associated with metastases and poorer prognosis in multivariate analysis. NSAID treatment results in a reduction of the incidence of colorectal adenoma in patients with familial adenomatous polyposis, in patients with a history of colorectal adenomas and in patients with a history of CRC. Pre-clinical research shows that COX-2 expression is associated with cell proliferation, angiogenesis, apoptosis inhibition and local immune-down modulation. An anticarcinogenic effect has been shown specifically in selective COX-2 inhibitors in animal models. Selective COX-2 inhibitors have fewer adverse effects than the non-selective NSAIDs and are promising chemopreventative and chemotherapeutical agents. The effects of selective COX-2 inhibition in the prevention of and treatment for colorectal carcinoma will be investigated in clinical randomized multicentre trials.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
dut
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0028-2162
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
8
|
|
pubmed:volume |
147
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2207-12
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14640057-Adenoma,
pubmed-meshheading:14640057-Adenomatous Polyposis Coli,
pubmed-meshheading:14640057-Animals,
pubmed-meshheading:14640057-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:14640057-Colorectal Neoplasms,
pubmed-meshheading:14640057-Cyclooxygenase 2,
pubmed-meshheading:14640057-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:14640057-Cyclooxygenase Inhibitors,
pubmed-meshheading:14640057-Humans,
pubmed-meshheading:14640057-Isoenzymes,
pubmed-meshheading:14640057-Membrane Proteins,
pubmed-meshheading:14640057-Neoplasm Metastasis,
pubmed-meshheading:14640057-Prognosis,
pubmed-meshheading:14640057-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:14640057-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
[Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
|
|
pubmed:affiliation |
Sint Lucas Andreas Ziekenhuis, locatie Lucas, afd. Heelkunde, Amsterdam. j.b.tuynman@amc.uva.nl
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
